AT442862T

Reduced-viscosity concentrated protein formulations

Abstract

stable liquid formulation comprising an immunoglobulin in an amount of at least 80 mg / ml and a salt and / or buffer in an amount of at least 100 mM, and having a kinematic viscosity of 50 mm 2 / s or less at 25 .

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

43 members in 14 offices

This recordMember, by publication datePriority claim4 more offices are in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
24010700United States of AmericaP
29383401United States of AmericaP
0142487United States of AmericaW

Members43

Family members, oldest first
DocumentOfficeKind
CA2423227A1CanadaA1
CA2751188A1CanadaA1
US2002045571A1United States of AmericaA1
WO0230463A2World Intellectual Property Organization (WIPO)A2
AU1344102AAustraliaA
WO0230463A3World Intellectual Property Organization (WIPO)A3
EP1324776A2European Patent Office (EPO)A2
IL155002A0IsraelA0
JP2004532798AJapanA
US6875432B2United States of AmericaB2
US2005175603A1United States of AmericaA1
AU2002213441B2AustraliaB2
US2007116700A1United States of AmericaA1
JP2009167190AJapanA
EP1324776B1European Patent Office (EPO)B1
JP4340062B2JapanB2
AT442862TThis recordAustriaT
ATE442862T2AustriaT2
DE60139944D1GermanyD1
EP2116265A2European Patent Office (EPO)A2
PT1324776EPortugalE
DK1324776T3DenmarkT3
SI1324776T1SloveniaT1
ES2332402T3SpainT3
US7666413B2United States of AmericaB2
EP2116265A3European Patent Office (EPO)A3
CA2423227CCanadaC
US8142776B2United States of AmericaB2
US2012076783A1United States of AmericaA1
US8703126B2United States of AmericaB2
IL231675A0IsraelA0
US2015044198A1United States of AmericaA1
CY1110547T1CyprusT1
IL155002AIsraelA
US2016367675A1United States of AmericaA1
IL231675AIsraelA
EP1324776B2European Patent Office (EPO)B2
ES2332402T5SpainT5
DK1324776T4DenmarkT4
SI1324776T2SloveniaT2
US10166293B2United States of AmericaB2
US2019231875A1United States of AmericaA1
EP2116265B1European Patent Office (EPO)B1